Novo Nordisk, Hims and Hers Shares Tumble on Severed Ties

Novo Nordisk (NVO) shares declined 5.3% following disappointing trial data for its obesity drug CagriSema, which showed no clear advantage over Eli Lilly's Zepbound, and the termination of its partnership with Hims & Hers Health (HIMS) for direct Wegovy access. This dual news event drove NVO to its sixth consecutive daily loss, while HIMS experienced its worst day on record, with both stocks seeing a surge in options trading, notably increased call volume for NVO and put volume for HIMS.

Analysis

Novo Nordisk (NVO) is facing significant headwinds from a dual negative catalyst event, causing a 5.3% stock decline to $69.90. Firstly, clinical trial data for its obesity drug CagriSema revealed no discernible advantage over Eli Lilly's (LLY) competing drug, Zepbound, diminishing the perceived strength of NVO's future product pipeline and its competitive edge. Secondly, Novo Nordisk terminated its partnership with Hims and Hers Health (HIMS), which had provided HIMS with direct access to the weight-loss drug Wegovy. This strategic shift has severely impacted HIMS, contributing to its worst trading day on record. From a technical standpoint, NVO's stock is on its sixth consecutive day of losses, now testing a key support level at $68 and reflecting a substantial 50.7% year-over-year deficit. The market reaction is further underscored by a surge in options activity for both companies, with call volume running at four times the average. Notably, sentiment in the options market appears divergent: bullish positioning is seen in NVO's most active August 100 calls, while fresh bearish bets are being placed on HIMS via new positions in its weekly 40-strike puts.

Key Decisions for Investors

• Investors should reassess Novo Nordisk's long-term competitive positioning against Eli Lilly, as the CagriSema trial data weakens its pipeline's perceived advantage in the critical obesity market.
• The termination of the Wegovy supply partnership represents a material risk to Hims & Hers Health's growth model, warranting scrutiny of its ability to secure alternative GLP-1 drug sources, a risk reflected in heavy put option activity.
• Monitor NVO's ability to hold the $68 technical support level, as a failure to do so could signal further downward momentum, while the high options volume suggests increased volatility for both NVO and HIMS.
• Consider the relative value implications of this news, which directly strengthens Eli Lilly's competitive standing at the expense of Novo Nordisk.